Effects of chronic therapy with cardiac contractility modulation electrical signals on cytoskeletal proteins and matrix metalloproteinases in dogs with heart failure

被引:39
作者
Rastogi, Sharad [1 ]
Mishra, Sudhish [1 ]
Zaca, Valerio [1 ]
Mika, Yuval [2 ]
Rousso, Benny [2 ]
Sabbah, Hani N. [1 ]
机构
[1] Henry Ford Hosp, Henry Ford Heart & Vasc Inst, Div Cardiovasc Med, Detroit, MI 48202 USA
[2] Impulse Dynam USA Inc, Orangeburg, NY USA
关键词
cytoskeletal proteins; titin; cardiac contractility modulation; heart failure;
D O I
10.1159/000112405
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: Therapy with cardiac contractility modulation (CCM) electrical signals delivered to left ventricular (LV) muscle during the absolute refractory period improves LV systolic and diastolic function in dogs with heart failure (HF). This study examined the effects of CCM therapy on mRNA and protein expression of cytoskeletal proteins, matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs) in the LV myocardium of dogs with HF. Methods: HF was produced in 14 dogs by coronary microembolizations. Dogs were randomized to 3 months of CCM therapy (n = 7) or to sham-operated controls (n = 7). LV tissue from 6 normal (NL) dogs was used for comparison. mRNA expression was measured using reverse-transcriptase polymerase chain reaction and protein expression using Western blots. Results: Compared with NL dogs, controls showed upregulation of mRNA and protein expression of the cytoskeletal proteins tubulin and fibronectin and MMP-1, MMP-2 and MMP-9, and downregulation of the cytoskeletal protein titin. Normalized expression of all these genes and proteins was seen after CCM therapy. No differences in expression of TIMP-1 and TIMP-2 were observed among groups. Conclusions: CCM therapy normalizes expression of key cytoskeletal proteins and MMPs and may partly explain the improvement in LV function seen in HF following CCM therapy. Copyright (c) 2007 S. Karger AG, Basel.
引用
收藏
页码:230 / 237
页数:8
相关论文
共 50 条
  • [21] Dynamics of Holter electrocardiogram monitoring in patients with chronic heart failure and atrial fibrillation on the background of cardiac contractility modulation
    Safiullina, Alfiya A.
    Uskach, Tatiana M.
    Sharapova, Yulduz S.
    Kochetov, Anatolii G.
    Sapelnikov, Oleg, V
    Tereshchenko, Sergey N.
    TERAPEVTICHESKII ARKHIV, 2021, 93 (09) : 1044 - 1051
  • [22] Application of the Fifth-Generation Cardiac Contractility Modulation Device in a Patient with Chronic Heart Failure: A Case Report
    Xie, Cui
    Xiang, Yang
    Wu, You
    Zhang, Youen
    INTERNATIONAL MEDICAL CASE REPORTS JOURNAL, 2024, 17 : 981 - 984
  • [23] Cardiac Contractility Modulation Improves Left Ventricular Function, Including Global Longitudinal Strain, in Patients with Chronic Heart Failure
    Raab, Cornelia
    Roehl, Peter
    Wiora, Matthias
    Ebelt, Henning
    JOURNAL OF CLINICAL MEDICINE, 2025, 14 (07)
  • [24] The effect of device-based cardiac contractility modulation therapy on myocardial efficiency and oxidative metabolism in patients with heart failure
    Georg Goliasch
    Aliasghar Khorsand
    Matthias Schütz
    Georgios Karanikas
    Cesar Khazen
    Heinz Sochor
    Herwig Schmidinger
    Michael Wolzt
    Senta Graf
    European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39 : 408 - 415
  • [25] The effect of device-based cardiac contractility modulation therapy on myocardial efficiency and oxidative metabolism in patients with heart failure
    Goliasch, Georg
    Khorsand, Aliasghar
    Schuetz, Matthias
    Karanikas, Georgios
    Khazen, Cesar
    Sochor, Heinz
    Schmidinger, Herwig
    Wolzt, Michael
    Graf, Senta
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 (03) : 408 - 415
  • [26] Cardiac Contractility Modulation Therapy: Should We Be Aiming Higher for Patients With Moderately Severe Heart Failure?
    Samii, Soraya
    Naccarelli, Gerald, V
    TEXAS HEART INSTITUTE JOURNAL, 2022, 49 (06)
  • [27] Comparative effects of rosuvastatin and allopurinol on circulating levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with chronic heart failure
    Tousoulis, Dimitris
    Andreou, Ioannis
    Tentolouris, Costas
    Antoniades, Charalambos
    Papageorgiou, Nikolaos
    Gounari, Panagiota
    Kotrogiannis, Iason
    Miliou, Antigoni
    Charakida, Marietta
    Trikas, Athanasios
    Stefanadis, Christodoulos
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2010, 145 (03) : 438 - 443
  • [28] Molecular effects of cardiac contractility modulation in patients with heart failure of ischemic aetiology uncovered by transcriptome analysis
    Lyasnikova, E.
    Sukhareva, K.
    Vander, M.
    Zaitsev, K.
    Firulyova, M.
    Sergushichev, A.
    Sorokina, M.
    Trukshina, M.
    Galenko, V.
    Lelyavina, T.
    Mitrofanova, L.
    Simonova, K.
    Abramov, M.
    Faggian, G.
    Luciani, G. B.
    Lebedev, D. S.
    Mikhaylov, E. N.
    Sitnikova, M.
    Kostareva, A.
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2024, 11
  • [29] Effects of cardiac resynchronization therapy on disease progression in chronic heart failure
    Donal, E
    Leclercq, C
    Linde, C
    Daubert, JC
    EUROPEAN HEART JOURNAL, 2006, 27 (09) : 1018 - 1025
  • [30] Acute Biomechanical Effects of Cardiac Contractility Modulation in Living Myocardial Slices from End-Stage Heart Failure Patients
    Bierhuizen, Mark F. A.
    Amesz, Jorik H.
    Langmuur, Sanne J. J.
    Lam, Bobby
    Knops, Paul
    Veen, Kevin M.
    Manintveld, Olivier C.
    Kluin, Jolanda
    de Groot, Natasja M. S.
    Taverne, Yannick J. H. J.
    BIOENGINEERING-BASEL, 2025, 12 (02):